Literature DB >> 2484144

The use of intravenous gammaglobulin in dengue fever, a case report.

D P Ascher1, H F Laws, C G Hayes.   

Abstract

We managed a serologically documented case of dengue fever with thrombocytopenia with IV IgG. Acute and convalescent ELISA and HI titers indicated an acute dengue infection with a secondary response that clinically, and by laboratory parameters dramatically improved after IV IgG administration. The use of IV IgG in cases of thrombocytopenia associated with dengue has both theoretical advantages and disadvantages. IV IgG may have a role in the management of DHF/DSS because of the significant morbidity and mortality associated with DHF/DSS. A prospective randomized study should be developed to determine if IV IgG does indeed effect the course of thrombocytopenia in dengue infections.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2484144

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  4 in total

1.  Assessing the prognosis of dengue-infected patients.

Authors:  Scott B Halstead; Lucy Cs Lum
Journal:  F1000 Med Rep       Date:  2009-09-28

2.  Efficacy of topical immunoglobulins against experimental adenoviral ocular infection.

Authors:  Edward C Nwanegbo; Eric G Romanowski; Y Jerold Gordon; Andrea Gambotto
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-09       Impact factor: 4.799

3.  Persistent thrombocytopenia following dengue shock syndrome.

Authors:  Utkarsh Kohli; Sunil Saharan; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2008-01       Impact factor: 1.967

4.  Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La Réunion.

Authors:  Patrick Gérardin; Georges Barau; Alain Michault; Marc Bintner; Hanitra Randrianaivo; Ghassan Choker; Yann Lenglet; Yasmina Touret; Anne Bouveret; Philippe Grivard; Karin Le Roux; Séverine Blanc; Isabelle Schuffenecker; Thérèse Couderc; Fernando Arenzana-Seisdedos; Marc Lecuit; Pierre-Yves Robillard
Journal:  PLoS Med       Date:  2008-03-18       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.